ReviewClinical drug investigation2021
Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Review in Clinical drug investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Pure red cell aplasia in a patient with rheumatoid arthritis after JAK inhibitor exposure-diagnostic challenges.Oxford medical case reports · 2026Article
- Filgotinib induces apoptosis in colorectal cancer cells by activating the p53 signaling pathway.Molecular biology reports · 2026Article
- Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort.Rheumatology and therapy · 2026Article
- Computational identification of small molecules for increased gene expression by synthetic circuits in mammalian cells.Nature communications · 2025Article
- Harnessing mesenchymal stem/stromal cells-based therapies for rheumatoid arthritis: mechanisms, clinical applications, and microenvironmental interactions.Stem cell research & therapy · 2025Review
- Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt.Current drug targets · 2025Review
- Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review.Biomedicines · 2023Review
- Signaling pathways in rheumatoid arthritis: implications for targeted therapy.Signal transduction and targeted therapy · 2023Review
- Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.Rheumatology and therapy · 2023Article
- Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives.Patient preference and adherence · 2023Review
- JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases.Frontiers in medicine · 2023Review
- Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review.Frontiers in medicine · 2023Review
- Targeting transcription factors for therapeutic benefit in rheumatoid arthritis.Frontiers in immunology · 2023Review
- Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies.Cells · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Filgotinib (Jyseleca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.